AI
Tuesday, July 15, 2014 10:21:14 AM
We look forward to completing the currently-enrolling Bridging Study that will vastly expand the Version 2 data package, and sharing top-line results in two weeks at #C4CT."
The Company is currently conducting a Version 1 vs. Version 2 Bridging Study (previously known as the Pilot Study) at BD Biosciences comparing Alzheimer's patients to cognitively intact, aged-matched controls to assess LymPro's accuracy in a head to head comparison across various univariate measurements and multivariate models. The study will provide the basis for the establishment of initial sensitivity and specificity in Version 1 and Version 2 of LymPro in the newly-analytically controlled LymPro conditions established at BD Biosciences. The Company expects to release topline Bridging Study data at the #C4CT Concussion Awareness Summit: TBI-induced Alzheimer's Disease to be held at the United Nations on July 31st.
VAYK Confirms Insider Buying at Open Market • VAYK • Nov 5, 2024 10:40 AM
Rainmaker Worldwide Inc. Announces Strategic Partnership Between Miranda Water Technologies and Fleming College • RAKR • Nov 4, 2024 12:03 PM
North Bay Resources Announces Assays up to 9.5% Copper at Murex Copper Project, British Columbia • NBRI • Nov 4, 2024 9:00 AM
Rainmaker Worldwide Inc. to Assume Direct, Non-Dealer Sales of Miranda Water Technologies in U.S. and Mexico in First Quarter of 2025 • RAKR • Nov 4, 2024 8:31 AM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
